Dr Reddy’s Posts Surprise Q3 Loss With NuvaRing Write-Off

Main Markets Strong But Compliance Issues Linger

Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.

India_moneybox_1200x675
Dr Reddy’s Posted A Surprise Loss In Its Financial Third Quarter • Source: Shutterstock

Dr Reddy's Laboratories, India’s second-largest drug company, plunged unexpectedly into the red in its financial thid quarter, hit by a $156.5m write-off related to its generic version of the NuvaRing (etonorgestrel/ethinyl estradiol) contraceptive. But a strong underlying performance, reflecting a string of US launches and a tight rein on costs, propelled the company’s shares to a 52-week high.

The company, which has been grappling with US regulatory compliance issues and falling product prices in the US, crashed to...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business